Icatibant Avansor

Icatibant, the active ingredient in Icatibant Avansor, is a bradykinin B2 receptor antagonist presented as a sterile solution for injection for subcutaneous administration. It is indicated for the treatment of acute hereditary angioedema attacks in patients who have a C1‑inhibitor deficiency, reducing swelling and pain associated with the condition.

GNH USA supplies Icatibant Avansor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this specialty therapy. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema. - Hereditary angioedema type I (C1‑inhibitor deficiency): rapidly reduces swelling during acute attacks. - Hereditary angioedema type II (functional C1‑inhibitor deficiency): provides prompt symptom relief. - Laryngeal edema associated with hereditary angioedema: helps prevent airway obstruction during an acute episode.

Icatibant may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Redness or swelling at injection site: localized erythema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness. - Flushing: temporary warmth or redness of the skin.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe injection‑site necrosis: tissue damage requiring medical attention. - Paradoxical angioedema: worsening swelling despite therapy. - Hypotension: marked drop in blood pressure. - Severe abdominal pain: may indicate visceral edema.

Before using Icatibant, consider the following safety measures. - Renal impairment: monitor renal function as the drug is primarily excreted unchanged. - Hepatic impairment: use with caution; limited data in severe liver disease. - Pregnancy: safety not established; weigh potential benefits against unknown risks. - Concomitant ACE inhibitors: may increase bradykinin levels and risk of angioedema. - Pediatric use: not studied in children; avoid unless specifically prescribed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that affect bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may exacerbate angioedema. - Angiotensin receptor blockers (ARBs): similar risk of increased bradykinin activity.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation. - Estrogen‑containing contraceptives: can worsen hereditary angioedema severity. - Diuretics: monitor blood pressure and electrolyte balance during therapy.